Drug intelligence / Profile preview

alpinia hainanensis extract

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Alpinia hainanensis extract is derived from the rhizome of the *Alpinia hainanensis* plant, a traditional ethnic medicine and food spice in Southwest China. Specifically, the EtOAc-soluble fraction of its ethanol extract has demonstrated the ability to ameliorate dextran sulfate sodium-induced ulcerative colitis. This extract is rich in various bioactive compounds, including diarylheptanoids, flavonoids, phenolics, and unique curcumin-butyrovanillone hybrids. It is being explored for its anti-inflammatory properties and its potential as a nutritional and dietary supplement for treating ulcerative colitis.

Targets

NF-κB

Beyond the preview

Go deeper on alpinia hainanensis extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpinia hainanensis extract.

Explore the full profile